Hemangiosarcoma in dogs, explained honestly and in full.

Hemangiosarcoma is a cancer of the cells that line blood vessels, which is why it can arise almost anywhere blood flows. In dogs it most often begins in the spleen, the heart (usually the right atrium), or the skin. Its danger is its stealth: a splenic tumor can grow large while the dog seems completely well, then rupture and bleed suddenly, so the first sign many owners ever see is an unexpected collapse. That is why it is so often caught late.

The prognosis numbers are hard, and we give them straight. According to PubMed, in the largest careful study of 208 dogs, median survival with splenectomy alone was 1.6 months, and clinical stage was the only factor significantly tied to how long a dog lived (Wendelburg et al., JAVMA, 2015). Other studies land a little higher, so across cohorts the honest range for surgery alone is about 1.6 to 3 months. A median is a midpoint, not a prediction: by definition, half of those dogs lived longer. Stage, meaning how far the cancer has spread by the time of surgery, matters more than age, breed, or size.

There is no cure for hemangiosarcoma today, but there is a real toolkit, and the honest theme running through all of it is that combinations beat any single treatment. The standard of care is surgery followed by doxorubicin-based chemotherapy, which extends survival modestly, in the early months especially, but not durably.

Immunotherapy is where much of the current hope sits, because the immune system can reach the microscopic cancer cells that surgery and chemotherapy miss, and occasionally produce long-term survivors that conventional therapy does not. The evidence must be read carefully. Some dog cancer vaccines are genuinely promising, some have been tested and shown no benefit, and some carry only conference-reported numbers never peer-reviewed. One newer vaccine targeting the tumor's blood supply reported one-year survival of 44% versus 14% for chemotherapy alone in a 23-dog study (Engbersen et al., 2025), while a rigorously tested HER2 vaccine in 118 dogs showed no significant benefit. The scoreboard below grades every option by its actual evidence.

Beyond vaccines, the toolkit includes checkpoint-inhibitor drugs, precision therapy matched to a tumor's mutations, and a targeted toxin called eBAT that raised six-month survival from under 40% to about 70% in an early trial (Borgatti et al., 2017). None is a cure alone; the better results come from combining them thoughtfully.

The one approach the rest of the field has left mostly unwritten for this cancer is the personalized neoantigen vaccine: instead of aiming at a target chosen in advance, it reads an individual dog's own tumor and builds a vaccine from that tumor's specific mutations. In human medicine this approach produced its clearest win yet, cutting the risk of melanoma recurrence or death by about 44% when added to immunotherapy (Weber et al., The Lancet, 2024). But that was human melanoma, one of the most heavily mutated cancers there is, and a result in people does not transfer automatically to dogs.

We should be equally honest about the challenge and about ourselves. Hemangiosarcoma is a hard case for this technology: it carries a modest mutation load and about half of tumors have no clear driver at all, leaving fewer targets to work with. And no cancer vaccine, including the personalized ones we design, has published canine efficacy data measured against the survival benchmarks above. The science is genuinely promising, which is why we pursue it, but nothing on the horizon changes those numbers today.

Whatever path you and your veterinarian choose, two practical steps protect your options. First, if any vaccine or personalized approach interests you even slightly, make sure the tumor is preserved properly at surgery, because how the tissue is stored decides what stays possible later. Second, ask your veterinary oncologist directly what stage your dog is and how it was determined, since that single answer shapes everything else. If you do not yet have a veterinary oncologist, your primary veterinarian can refer you.